Sorted By:

Relevance


Loretta Shares a Story of Hope in the Face of Her Cancer Diagnosis

PhRMA  |  Blog Post

Annually, 580,000 Americans lose their battle with cancer, equating to 1,600 deaths daily.
http://catalyst.phrma.org/loretta-shares-a-story-of-hope-in-the-face-of-her-cancer-diagnosis

Insurance coverage 101

PhRMA  |  Blog Post

Watch our Health Insurance 101 video for a quick refresher: Whether your insurance comes from your employer, a health insurance exchange or shop on your own, we’re about to enter open enrollment season.
http://catalyst.phrma.org/insurance-coverage-101

Washington State Research Institutions Have Conducted More Than 3,600 Clinical Trials of New Medicines Since 1999

PhRMA  |  Press Release

Over 370 trials testing a potential medicine for a chronic disease are still active and recruiting Washington patients to participate, offering hope for disease sufferers who seek treatments that are best for them and an opportunity to discuss therapeutic options with their physicians.
https://www.phrma.org/press-release/washington-state-research-institutions-have-conducted-more-than-3-600-clinical-trials-of-new-medicines-since-1999

New Research Highlights “Rare Opportunity” to Improve Health Outcomes, Affordability through Targeted Medication Adherence Efforts

PhRMA  |  Press Release

Of the notable findings, the report showed that poor medication adherence was associated with additional medical and hospital visits resulting in otherwise avoidable spending for Medicare Part A and B services in the range of $49 to $840 per beneficiary per month.
https://www.phrma.org/press-release/new-research-highlights-rare-opportunity-to-improve-health-outcomes-affordability-through-targeted-medication-adherence-efforts

Focusing on Only 1% of Spending Will Not Solve Nation’s Health Care Challenges

PhRMA  |  Blog Post

Commentary published today in Mayo Clinic Proceedings highlights a critical challenge facing cancer patients: the ability to access the medicines they need.
http://catalyst.phrma.org/focusing-on-only-1-of-spending-will-not-solve-nations-health-care-challenges

Release: Medicines In Development for Rare Diseases

PhRMA  |  Press Release

The number jumped to 176 in 1991, to 303 in 2007 and to 460 today.
https://www.phrma.org/press-release/release-medicines-in-development-for-rare-diseases

Strong R&D Investment the Best Bet to Slow Alzheimer’s Growing Threat

PhRMA  |  Blog Post

 Medicaid costs will increase 330%, from $41 billion to $176 billion.
http://catalyst.phrma.org/strong-rd-investment-the-best-bet-to-slow-alzheimers-growing-threat

I’m Not Average: Jack’s Journey Battling Rare Blood Cancer

PhRMA  |  Blog Post

Although his cancer has returned, Jack is able to continue controlling his disease thanks to scientific research and innovation.
http://catalyst.phrma.org/im-not-average-jacks-journey-battling-rare-blood-cancer

New Video: How Medicines Can Curb Health Care Costs

PhRMA  |  Blog Post

  In many cases, research and medicines from the biopharmaceutical sector are the only hope for survival for patients and their families.
http://catalyst.phrma.org/new-video-how-medicines-can-curb-health-care-costs

Medicines in Development: Vaccines

PhRMA  |  Press Release

To learn about the nearly 300 vaccines in development for both preventative and therapeutic uses, see PhRMA’s new Vaccines in Development report.
https://www.phrma.org/press-release/medicines-in-development-vaccines

Burden on Patients: 5 Questions on access to multiple sclerosis medicines in health exchange plans

PhRMA  |  Blog Post

The Society also invested $50.2 million to support more than 380 new and ongoing research projects around the world.
http://catalyst.phrma.org/burden-on-patients-5-questions-on-access-to-multiple-sclerosis-medicines-in-health-exchange-plans

PhRMA Statement Supporting House Vote on Biosimilars

PhRMA  |  Press Release

As of 2008, more than 300 biologics had been approved by the Food and Drug Administration and 633 biotechnology medicines were in development, including more than 250 for various cancers.
https://www.phrma.org/press-release/phrma-statement-supporting-house-vote-on-biosimilars

PhRMA Foundation Announces New Young Investigator Grantees to Advance Medication Adherence Research

PhRMA  |  Press Release

The cost of nonadherence has been estimated by researchers to cost the U.S. health care system $100 billion to $300 billion annually, including costs from avoidable hospitalizations, nursing home admissions, and premature deaths.
https://www.phrma.org/press-release/phrma-foundation-announces-new-young-investigator-grantees-to-advance-medication-adherence-research

Fact Check Friday: Biopharmaceutical company communications with payers

PhRMA  |  Blog Post

Today, we’re examining how and what biopharmaceutical companies communicate with payers about a medicine prior to its approval by the U.S.
http://catalyst.phrma.org/fact-check-friday-biopharmaceutical-company-communications-with-payers

Matt and Jamie share their stories in new “From Hope to Cures” ads

PhRMA  |  Blog Post

Jamie, a vibrant woman diagnosed with a rare blood cancer 15 years ago is thriving today thanks to advancements in treatments.
http://catalyst.phrma.org/matt-and-jamie-share-their-stories-in-new-from-hope-to-cures-ads

The Best Kind of Progress: Cancer Medicines and the Value They Bring to Us All

PhRMA  |  Blog Post

  Of those, about 80 percent have the potential to be first-in-class treatments Does anyone really want to slow this progress?
http://catalyst.phrma.org/the-best-kind-of-progress-cancer-medicines-and-the-value-they-bring-to-us-all

ICYMI: The New York Times Highlights How Increasing Cost Sharing Hinders Access, Raises Other Health Care Costs

PhRMA  |  Blog Post

Visit .org/patient-profile/rheumatoid-arthritis?
http://catalyst.phrma.org/icymi-the-new-york-times-highlights-how-increasing-cost-sharing-hinders-access-raises-other-health-care-costs

ICYMI: Coverage of expensive drugs tops patients’ concerns

PhRMA  |  Blog Post

More than 300 patient advocacy groups recently wrote Health and Human Services Secretary Sylvia Mathews Burwell to complain about some insurer tactics that "are highly discriminatory against patients with chronic health conditions and may ... violate the (law's) nondiscrimination provisions."
http://catalyst.phrma.org/icymi-coverage-of-expensive-drugs-tops-patients-concerns

What They Are Saying about the Value of New Innovative Medicines

PhRMA  |  Blog Post

Prescription drug spending has remained consistent despite biopharmaceutical companies bringing more than 400 new medicines to patients over the past 15 years.
http://catalyst.phrma.org/what-they-are-saying-about-the-value-of-new-innovative-medicines

Continuing progress and promise in pediatric drug development

PhRMA  |  Blog Post

However, this progress has come with new challenges.
http://catalyst.phrma.org/continuing-progress-and-promise-in-pediatric-drug-development

Researchers and Patient Advocates Honored with PhRMA Award

PhRMA  |  Press Release

Such a treatment could help save Medicare and Medicaid $140 billion annually in 2030, and could save the U.S. health care system $447 billion annually by 2050, according to the Alzheimer’s Association.
https://www.phrma.org/press-release/researchers-and-patient-advocates-honored-with-phrma-award

Two Women Scientists Honored With Discoverers Award For First New Oral Medication for Diabetes in Over a Decade

PhRMA  |  Press Release

fs=1&amp;hl=en_US&amp;rel=0" type="application/x-shockwave-flash" allowscriptaccess="always" allowfullscreen="true" width="640" ></embed></object> The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country’s leading pharmaceutical research and biotechnology companies, which are devoted to inventing medicines that allow patients to live longer, healthier, and more productive lives.
https://www.phrma.org/press-release/two-women-scientists-honored-with-discoverers-award-for-first-new-oral-medication-for-diabetes-in-over-a-decade

PhRMA Statement on the FDA Approving Biosimilars

PhRMA  |  Press Release

As of 2008, more than 300 biologics had been approved by the Food and Drug Administration (FDA) and 633 biotechnology medicines were in development, including more than 250 for various cancers.
https://www.phrma.org/press-release/phrma-statement-on-the-fda-approving-biosimilars

R&D Investment by U.S. Biopharmaceutical Companies Remains Strong Despite Ongoing Economic Challenges

PhRMA  |  Press Release

The current pipeline includes more than 800 medicines to treat cancer, over 300 specific to rare diseases and more than 300 medicines for heart disease and stroke.
https://www.phrma.org/press-release/randd-investment-by-u-s-biopharmaceutical-companies-remains-strong-despite-ongoing-economic-challenges

PhRMA Statement on Clinical Trials and Bad Pharma

PhRMA  |  Press Release

Goldacre often cites a January 2013 study published in the British Medical Journal that purported to evaluate whether trial results were present on ClinicalTrials.gov for records that the authors deemed to require results reporting under FDAAA.
https://www.phrma.org/press-release/phrma-statement-on-clinical-trials-and-bad-pharma

You have reviewed the first 375 results out of 430. Each page contains 25 results. You're on page 15.

prev 13 14 15 16 17 18 next